Ken Griffin Castle Biosciences Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 12,400 shares of CSTL stock, worth $406,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,400

Previous 36,300 65.84%

Holding current value

$406,472

Previous $804,000 66.54%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$18.84 - $24.94 $708,741 - $938,217	37,619 Added 5.74%	693,385 $15.1 Million
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $5.91 Million - $8.27 Million	327,017 Added 99.47%	655,766 $14.5 Million
Q4 2023 Feb 14, 2024	SELL	$12.19 - $22.43 $2.31 Million - $4.25 Million	-189,309 Reduced 36.54%	328,749 $7.09 Million
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $6.13 Million - $9.37 Million	461,775 Added 820.45%	518,058 $8.75 Million
Q2 2023 Aug 14, 2023	SELL	$11.66 - $26.0 $7.05 Million - $15.7 Million	-604,673 Reduced 91.48%	56,283 $772,000
Q1 2023 May 15, 2023	BUY	$19.47 - $28.49 $2.13 Million - $3.12 Million	109,641 Added 19.89%	660,956 $15 Million
Q4 2022 Feb 14, 2023	SELL	$18.08 - $30.0 $3.28 Million - $5.44 Million	-181,340 Reduced 24.75%	551,315 $13 Million
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $2.3 Million - $3.5 Million	102,059 Added 16.18%	732,655 $19.1 Million
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $7.1 Million - $20.4 Million	443,589 Added 237.2%	630,596 $13.8 Million
Q1 2022 May 16, 2022	BUY	$33.17 - $46.98 $2.96 Million - $4.19 Million	89,121 Added 91.05%	187,007 $8.39 Million
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $5.18 Million - $8.96 Million	-132,553 Reduced 57.52%	97,886 $4.2 Million
Q3 2021 Nov 15, 2021	BUY	$60.13 - $77.6 $10.2 Million - $13.2 Million	170,434 Added 284.03%	230,439 $15.3 Million
Q2 2021 Aug 16, 2021	SELL	$50.07 - $76.78 $4,356 - $6,679	-87 Reduced 0.14%	60,005 $4.4 Million
Q1 2021 May 17, 2021	BUY	$58.92 - $97.33 $2.95 Million - $4.88 Million	50,103 Added 501.58%	60,092 $4.11 Million
Q4 2020 Feb 16, 2021	SELL	$43.6 - $73.05 $2.17 Million - $3.64 Million	-49,807 Reduced 83.29%	9,989 $670,000
Q3 2020 Nov 16, 2020	SELL	$38.47 - $52.03 $61,782 - $83,560	-1,606 Reduced 2.62%	59,796 $3.08 Million
Q2 2020 Aug 14, 2020	BUY	$27.28 - $43.01 $1.68 Million - $2.64 Million	61,402 New	61,402 $2.32 Million
Q1 2020 May 15, 2020	SELL	$23.08 - $35.53 $205,411 - $316,217	-8,900 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$15.74 - $35.04 $342,738 - $762,996	-21,775 Reduced 70.99%	8,900 $305,000
Q3 2019 Nov 14, 2019	BUY	$18.09 - $27.92 $554,910 - $856,446	30,675 New	30,675 $554,000

Others Institutions Holding CSTL

# of Institutions

183

Shares Held

26.1M

Call Options Held

511K

Put Options Held

100

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $862M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account